TP53 and posterior cortical atrophy: It increases in metastatic PCa, in ADT-recurrent PCa, in castration-resistant stages, and particularly in neuroendocrine PCa (NEPC) [103,104], where it is nearly universal (often alongside TP53 and PTEN alterations), compared to primary tumors [7,9,25].